News list for "propanc"
Australia-based Propanc Biopharma (NASDAQ: PPCB) said on Monday it has raised up to $100 million from Hexstone Capital, a family office active in Bitcoin, Ethereum, Solana, Dogecoin and other digital assets. The private placement transaction, structured through convertible preference shares, provides Propanc with an initial investment of $1 million and an initial investment over the next year.
总部位于澳大利亚的 Propanc Biopharma（纳斯达克股票代码为 PPCB）周一表示，已从 Hexstone Capital 获得高达1 亿美元的融资。Hexstone Capital 是一家活跃于比特币、以太坊、索拉纳、狗狗币和其他数字资产领域的家族办公室。 这项通过可转换优先股构建的私募交易，为 Propanc 提供了 100 万美元的初始投资，并在未来一年内提供...
On November 4th, according to Globenewswire, digital asset finance company Propanc Biopharma (NASDAQ: PPCB) announced a strategic plan to acquire digital asset management (DAT) companies that are currently trading below their market capitalization-to-net asset value (MNAV) ratios. Company management believes that the acquisition of undervalued digital asset technology (DAT) companies is a way to strengthen Propanc's balance sheet, diversify its assets and create long-term stocks...
11月4日消息，据Globenewswire报道，数字资产财务公司Propanc Biopharma（纳斯达克股票代码：PPCB）宣布了一项战略计划，旨在收购目前市值与净资产值之比（MNAV）低于其交易的数字资产管理（DAT）公司。公司管理层认为，收购被低估的数字资产技术（DAT）公司是增强Propanc资产负债表、实现资产多元化并创造长期股...
On October 15th, Propanc Biopharma, a biopharmaceutical company that adopts the Ethereum treasury strategy, announced a strategic financing agreement of up to $100 million with the family office Hexstone Capital. Propanc CEO James Nathanielsz said that the financing will accelerate the development of the company's clinical pipeline and plans to grow the value of the digital asset library to $100 million or more in the next 12 months. Hexstone Capital has previously invested in several companies ...
10 月 15 日消息，采用以太坊财库战略的生物制药公司 Propanc Biopharma 宣布与家族办公室 Hexstone Capital 达成最高 1 亿美元的战略融资协议。 Propanc CEO James Nathanielsz 表示，此次融资将加速公司临床管线开发，并计划在未来 12 个月内将数字资产库价值增长至 1 亿美元或以上。Hexstone Capital 此前已投资多家拥有数字资产库的公司，涉及 BTC、ETH、SOL、DOGE 等多种数字资产。 此前消息，九月初...
Biopharmaceutical company Propanc Biopharma (NASDAQ: PPCB) today (Sept 2) announced plans to acquire $100 million worth of Ethereum over the next 12 months. The company says the move will strengthen its corporate strategy across multiple areas, including cryptocurrency investments, drug development, and asset acquisitions.
生物制药公司Propanc Biopharma(纳斯达克股票代码:PPCB)今日(9月2日)宣布计划在未来12个月内收购价值1亿美元的以太坊。该公司表示，此举将增强其在加密货币投资、药物开发和资产收购等多方面的企业战略。
